REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2021 >

Decisions 27th April 2021

At the meeting on the 27th April the following decisions were agreed

 

New Drug Requests

Approved

Methoxyflurane (inhaled) (Penthrox®) (TLS Red)

  • Adjunct for moderate to severe pain for women undergoing ambulatory gynaecology procedures

Evorel® Conti patch

  • (estradiol & norethisterone)

Lenzetto® transdermal spray

  • (estradiol)
  • Reserved for patients where transdermal treatment is indicated (e.g. oral HRT contra-indicated, not tolerated or ineffective) and where transdermal patches are inappropriate.

Shared Care Protocols/TLS changes

TLS changes:

  • Mycophenolate for autoimmune hepatitis and inflammatory bowel disease changed from TLS Red to TLS Amber 3 months to be incorporated into existing shared care protocol for rheumatological conditions.  TLS change pending updated shared care protocol approval at JFG. 

Other Formulary Decisions:

  • A system wide review of melatonin is to be completed.  No individual melatonin new drug requests will be considered until full melatonin review is complete.